SML4054
AFQ056
≥98% (HPLC)
别名:
(3aR,4S,7aR)-Octahydro-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-1H-indole-1-carboxylic acid methyl ester, AFQ 056, Mavoglurant
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C19H23NO3
化学文摘社编号:
分子量:
313.39
UNSPSC Code:
12352200
MDL number:
NACRES:
NA.21
InChI key
ZFPZEYHRWGMJCV-ZHALLVOQSA-N
SMILES string
O[C@]1(C#CC2=CC(C)=CC=C2)[C@@]3([H])[C@@](N(C(OC)=O)CC3)([H])CCC1
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
Orally active, potent and selective mGluR5 antagonist.
AFQ056 (Mavoglurant) is an orally active, potent and selective antagonist of metabotropic glutamate receptor 5 (mGluR5). AFQ056 was investigated for treatment of fragile X syndrome and for Parkinson′s disease.
AFQ056 (Mavoglurant) is an orally active, potent and selective antagonist of metabotropic glutamate receptor 5 (mGluR5). AFQ056 was investigated for treatment of fragile X syndrome and for Parkinson′s disease.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Laurent Grégoire et al.
Parkinsonism & related disorders, 17(4), 270-276 (2011-02-15)
Overactivity of glutamatergic transmission has been implicated in Parkinson's disease (PD) and levodopa (L-Dopa)-induced dyskinesias. Striatal metabotropic glutamate receptors type 5 (mGluR5) are abundant and provide specific targets to modulate glutamatergic activity. This study investigated the acute effects of the
Kirstie A Bennett et al.
The Journal of pharmacology and experimental therapeutics, 377(1), 157-168 (2021-02-06)
The metabotropic glutamate receptor 5 (mGlu5) is a recognized central nervous system therapeutic target for which several negative allosteric modulator (NAM) drug candidates have or are continuing to be investigated for various disease indications in clinical development. Direct measurement of
Sébastien Jacquemont et al.
Science translational medicine, 3(64), 64ra1-64ra1 (2011-01-07)
Fragile X syndrome (FXS) is an X-linked condition associated with intellectual disability and behavioral problems. It is caused by expansion of a CGG repeat in the 5' untranslated region of the fragile X mental retardation 1 (FMR1) gene. This mutation
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持